Kidney function key to new Drug's safety
NCT ID NCT06496217
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how the experimental drug MBX 2109 is handled by the body in people with different levels of kidney function. 25 adults with normal or impaired kidneys received a single dose. The goal was to measure safety and drug levels, not to treat a disease. Results will help decide future doses for patients with kidney issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MBX Bioscience Investigational Site
Tampa, Florida, 33603, United States
-
MBX Biosciences Investigational Site
Miami, Florida, 33136, United States
-
MBX Biosciences Investigational Site
Minneapolis, Minnesota, 55101, United States